1. Vandeleur CL, Fassassi S, Castelao E, Glaus J, Strippoli MF, Lasserre AM, Rudaz D, Gebreab S, Pistis G, Aubry JM, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry research. 2017;250:50–8.
2. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, Yu Y, Kou C, Xu X, Lu J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. The lancet Psychiatry. 2019;6(3):211–24.
3. Kelley ME, Dunlop BW, Nemeroff CB, Lori A, Carrillo-Roa T, Binder EB, Kutner MH, Rivera VA, Craighead WE, Mayberg HS. Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. Depress Anxiety. 2018;35(10):992–1000.
4. Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remissionin depression. Journal of Psychiatry Neuroscience Jpn. 2002;27(4):241–7.
5. Lohoff FW, Ferraro TN. Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010;11(3):423–39.
6. Mocking RJ, Figueroa CA, Rive MM, Geugies H, Servaas MN, Assies J, Koeter MW, Vaz FM, Wichers M, van Straalen JP, et al. Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study. BMJ open. 2016;6(3):e009510.
7. Bigdeli TB, Ripke S, Peterson RE, Trzaskowski M, Bacanu SA, Abdellaoui A, Andlauer TF, Beekman AT, Berger K, Blackwood DH, et al. Genetic effects influencing risk for major depressive disorder in China and Europe. Translational psychiatry. 2017;7(3):e1074.
8. Vall E, Wade TD. Predictors of treatment outcome in individuals with eating disorders: A systematic review and meta-analysis. Int J Eat Disord. 2015;48(7):946–71.
9. Lin E, Lane HY. Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics. 2015;16(5):555–66.
10. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition. 2000;16(7–8):544.
11. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002;159(12):2099.
12. Jain R, Jackson WC. Beyond the resistance: how novel neurobiological understandings of depression may lead to advanced treatment strategies. J Clin Psychiatry. 2012;73(11):e30.
13. Alpert JE, Mischoulon D, Rubenstein GEF, Bottonari K, Nierenberg AA, Fava M. Folinic Acid (Leucovorin) as an Adjunctive Treatment for SSRI-Refractory Depression. Ann Clin Psychiatry. 2002;14(1):33–8.
14. Hintikka J, Tolmunen T, Tanskanen A, Viinamaki H. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. BMC Psychiatry. 2003;3:17.
15. McGuffin P, Knight J, Breen G, Brewster S, Boyd PR, Craddock N, Gill M, Korszun A, Maier W, Middleton L, et al. Whole genome linkage scan of recurrent depressive disorder from the depression network study. Human molecular genetics. 2005;14(22):3337–45.
16. Cortese C, Motti C. MTHFR gene polymorphism, homocysteine and cardiovascular disease. Public Health Nutr. 2001;4(2B):493–7.
17. Santos M, Kovari E, Hof PR, Gold G, Bouras C, Giannakopoulos P. The impact of vascular burden on late-life depression. Brain Res Rev. 2009;62(1):19–32.
18. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165(1):1–13.
19. Gaysina D, Cohen S, Craddock N, Farmer A, Hoda F, Korszun A, Owen MJ, Craig IW, McGuffin P. No association with the 5,10-methylenetetrahydrofolate reductase gene and major depressive disorder: results of the depression case control (DeCC) study and a meta-analysis. American journal of medical genetics Part B Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2008;147B(6):699–706.
20. Maes M, Smith R, Christophe A, Vandoolaeghe E, Gastel AV, Neels H, Demedts P, Wauters A, Meltzer HY. Lower serum high-density lipoprotein cholesterol (HDL‐C) in major depression and in depressed men with serious suicidal attempts: relationship with immune‐inflammatory markers. Acta psychiatrica Scandinavica. 1997;95(3):212.
21. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103(15):5644–51.
22. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. 1992;340(8824):879–80.
23. Sharpley F. C: The Role of Genes (and Environmental Stress) in Depression: An Update. Current Psychiatry Reviews. 2011;7(2):84–95.
24. Kim YS, Gu BH, Choi BC, Kim MS, Song S, Yun JH, Chung MK, Choi CH, Baek KH. Apolipoprotein A-IV as a novel gene associated with polycystic ovary syndrome. Int J Mol Med. 2013;31(3):707–16.
25. Diniz BS, Lin CW, Sibille E, Tseng G, Lotrich F, Aizenstein HJ, Reynolds CF, Butters MA. Circulating biosignatures of late-life depression (LLD): Towards a comprehensive, data-driven approach to understanding LLD pathophysiology. J Psychiatr Res. 2016;82:1–7.
26. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci. 2001;22(2):75–83.
27. Association AP. Diagnostic and statistic manual of mental disorders 5 (DSM-5). Diabetes. 1994;11(Suppl)(1):97–8.
28. Takahashi. Rating scale for depression. Journal of Neurology Neurosurgery Psychiatry. 1998;23(1):56–62.
29. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2002;3(1):5–43.
30. Kamphuis MH, Geerlings MI, Grobbee DE, Kromhout D. Dietary intake of B(6-9-12) vitamins, serum homocysteine levels and their association with depressive symptoms: the Zutphen Elderly Study. Eur J Clin Nutr. 2008;62(8):939–45.
31. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuro-psychopharmacol Biol Psychiatry. 2005;29(7):1103–12.
32. Herrmann W, Obeid R. Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid. Clinical chemistry laboratory medicine. 2007;45(12):1614–20.
33. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry. 1988;145(9):1110–4.
34. Christensen H, Aiken A, Batterham PJ, Walker J, Mackinnon AJ, Fenech M, Hickie IB. No clear potentiation of antidepressant medication effects by folic acid + vitamin B12 in a large community sample. J Affect Disord. 2011;130(1–2):37–45.
35. Nanri A, Mizoue T, Matsushita Y, Sasaki S, Ohta M, Sato M, Mishima N. Serum folate and homocysteine and depressive symptoms among Japanese men and women. Eur J Clin Nutr. 2010;64(3):289–96.
36. Kalra DK. Homocysteine and cardiovascular disease. Curr Atheroscler Rep. 2004;6(2):101–6.
37. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69(2):228–32.
38. Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, Gordon J, Israel JA, Tedlow JR, Lamon-Fava S, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002;43(4):310–6.
39. Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, Demedts P, Wauters A, Meltzer HY. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta psychiatrica Scandinavica. 1997;95(3):212–21.
40. Mischoulon D, Fava M. Docosahexanoic acid and omega-3 fatty acids in depression. Psychiatr Clin North Am. 2000;23(4):785–94.
41. Murphy GM, Kremer C, Rodrigues H, Schatzberg AF. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry. 2003;54(7):665–73.
42. Schmand B, Hooijer C, Jonker C, Lindeboom J, Havekes LM. Apolipoprotein E phenotype is not related to late-life depression in a population-based sample. Soc Psychiatry Psychiatr Epidemiol. 1998;33(1):21–6.
43. Mauricio M, O'Hara R, Yesavage JA, Friedman L, Kraemer HC, Van De Water M, Murphy GM Jr. A longitudinal study of apolipoprotein-E genotype and depressive symptoms in community-dwelling older adults. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2000;8(3):196–200.
44. Bizzarro A, Seripa D, Acciarri A, Matera MG, Pilotto A, Tiziano FD, Brahe C, Masullo C. The complex interaction between APOE promoter and AD: an Italian case-control study. European journal of human genetics: EJHG. 2009;17(7):938–45.
45. Lescai F, Chiamenti AM, Codemo A, Pirazzini C, D'Agostino G, Ruaro C, Ghidoni R, Benussi L, Galimberti D, Esposito F, et al. An APOE haplotype associated with decreased epsilon4 expression increases the risk of late onset Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2011;24(2):235–45.
46. Groenendijk M, Cantor RM, de Bruin TW, Dallinga-Thie GM. The apoAI-CIII-AIV gene cluster. Atherosclerosis. 2001;157(1):1–11.